Cargando…

Role of AXL expression in non-small cell lung cancer

The present study aimed to investigate the expression profile of AXL in non-small cell lung cancer (NSCLC) and its clinical significance. The current study included 257 NSCLC patients, tyrosine-protein kinase receptor UFO (AXL) expression in paired lung cancer and adjacent normal lung tissues of NSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Xiaohan, Liu, Jinlu, Zhong, Xinwen, Li, Xi, Zhang, Qigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228461/ https://www.ncbi.nlm.nih.gov/pubmed/28105215 http://dx.doi.org/10.3892/ol.2016.5356

Ejemplares similares

PIWIL2 promotes progression of non-small cell lung cancer by inducing CDK2 and Cyclin A expression
por: Qu, Xiaohan, et al.
Publicado: (2015)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC
por: Yang, Shize, et al.
Publicado: (2017)

1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer
por: Ramkumar, K., et al.
Publicado: (2020)

Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer
por: Nuzzo, Silvia, et al.
Publicado: (2019)

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
por: Jeong, Inae, et al.
Publicado: (2019)

Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer
por: ZHONG, XINWEN, et al.
Publicado: (2014)

Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells
por: Kim, Nam-Yi, et al.
Publicado: (2020)

AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases
por: Wu, Xiaoliang, et al.
Publicado: (2017)

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
por: Yoshimura, Akihiro, et al.
Publicado: (2022)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Intervention of AXL in EGFR Signaling via Phosphorylation and Stabilization of MIG6 in Non-Small Cell Lung Cancer
por: Yang, Ya-Yu, et al.
Publicado: (2023)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer
por: Cao, Bihui, et al.
Publicado: (2022)

Expression of CENPE and its Prognostic Role in Non-small Cell Lung Cancer
por: Hao, Xuezhi, et al.
Publicado: (2019)

Mechanism research of miR‐34a regulates Axl in non‐small‐cell lung cancer with gefitinib‐acquired resistance
por: Xiong, Ran, et al.
Publicado: (2019)

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020)

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
por: Tian, Yaqiong, et al.
Publicado: (2016)

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
por: Kim, Donghwa, et al.
Publicado: (2019)

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
por: Sato, Katsuaki, et al.
Publicado: (2016)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
por: Sun, Qi, et al.
Publicado: (2022)

RFC3 induces epithelial-mesenchymal transition in lung adenocarcinoma cells through the Wnt/β-catenin pathway and possesses prognostic value in lung adenocarcinoma
por: Gong, Shulei, et al.
Publicado: (2019)

Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer
por: Linger, Rachel M.A., et al.
Publicado: (2012)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Expression of Axl and its prognostic significance in human breast cancer
por: Jin, Gaoyuan, et al.
Publicado: (2017)

The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression
por: Dong, Siyuan, et al.
Publicado: (2015)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2020)

Role of tesmin expression in non-small cell lung cancer
por: Grzegrzolka, Jedrzej, et al.
Publicado: (2021)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
por: Ikeda, Mio, et al.
Publicado: (2020)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
por: Nonagase, Yoshikane, et al.
Publicado: (2019)

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
por: Wang, Tong-Hong, et al.
Publicado: (2020)

The role of E-cadherin expression in non-small cell lung cancer.
por: Lim, S. C., et al.
Publicado: (2000)

Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy
por: Kanzaki, Ryu, et al.
Publicado: (2017)

Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
por: Kim, Kyung-Chan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_99s8ho7s5h84kb3ma4u3tgtmno